373 related articles for article (PubMed ID: 31330410)
1. Evaluation of [
Jiang H; Zhang R; Jiang H; Zhang M; Guo W; Feng G; Pan W; Xu H; Wang S
Nucl Med Biol; 2019; 72-73():36-44. PubMed ID: 31330410
[TBL] [Abstract][Full Text] [Related]
2. Screening of radiotracer for diagnosis of colorectal cancer liver metastasis based on MACC1-SPON2.
Jiang H; Guo W; Huang K; Jiang H; Zhang R; Hu H; Lin X; Wang S
Abdom Radiol (NY); 2021 Jul; 46(7):3227-3237. PubMed ID: 33712897
[TBL] [Abstract][Full Text] [Related]
3. Using dual-tracer PET to predict the biologic behavior of human colorectal cancer.
Wang H; Zhang J; Tian J; Qu B; Li T; Chen Y; Liu J; Wang S
J Nucl Med; 2009 Nov; 50(11):1857-64. PubMed ID: 19837754
[TBL] [Abstract][Full Text] [Related]
4. Interobserver agreement of qualitative analysis and tumor delineation of 18F-fluoromisonidazole and 3'-deoxy-3'-18F-fluorothymidine PET images in lung cancer.
Thureau S; Chaumet-Riffaud P; Modzelewski R; Fernandez P; Tessonnier L; Vervueren L; Cachin F; Berriolo-Riedinger A; Olivier P; Kolesnikov-Gauthier H; Blagosklonov O; Bridji B; Devillers A; Collombier L; Courbon F; Gremillet E; Houzard C; Caignon JM; Roux J; Aide N; Brenot-Rossi I; Doyeux K; Dubray B; Vera P
J Nucl Med; 2013 Sep; 54(9):1543-50. PubMed ID: 23918733
[TBL] [Abstract][Full Text] [Related]
5. Correlation of (18)F-fluoromisonidazole PET findings with HIF-1α and p53 expressions in head and neck cancer: comparison with (18)F-FDG PET.
Norikane T; Yamamoto Y; Maeda Y; Kudomi N; Matsunaga T; Haba R; Iwasaki A; Hoshikawa H; Nishiyama Y
Nucl Med Commun; 2014 Jan; 35(1):30-5. PubMed ID: 24121312
[TBL] [Abstract][Full Text] [Related]
6. Detection of colorectal cancer using ¹⁸F-FLT PET: comparison with ¹⁸F-FDG PET.
Yamamoto Y; Kameyama R; Izuishi K; Takebayashi R; Hagiike M; Asakura M; Haba R; Nishiyama Y
Nucl Med Commun; 2009 Nov; 30(11):841-5. PubMed ID: 19773672
[TBL] [Abstract][Full Text] [Related]
7. Reproducibility of static and dynamic (18)F-FDG, (18)F-FLT, and (18)F-FMISO MicroPET studies in a murine model of HER2+ breast cancer.
Whisenant JG; Peterson TE; Fluckiger JU; Tantawy MN; Ayers GD; Yankeelov TE
Mol Imaging Biol; 2013 Feb; 15(1):87-96. PubMed ID: 22644988
[TBL] [Abstract][Full Text] [Related]
8. Micro-positron emission tomography imaging of angiogenesis based on
Zhang MY; Jiang HJ; Jiang H; Zhang RJ; Wang ZC
Hepatobiliary Pancreat Dis Int; 2021 Aug; 20(4):345-351. PubMed ID: 33753000
[TBL] [Abstract][Full Text] [Related]
9. Potential impact of [18F]3'-deoxy-3'-fluorothymidine versus [18F]fluoro-2-deoxy-D-glucose in positron emission tomography for colorectal cancer.
Francis DL; Visvikis D; Costa DC; Arulampalam TH; Townsend C; Luthra SK; Taylor I; Ell PJ
Eur J Nucl Med Mol Imaging; 2003 Jul; 30(7):988-94. PubMed ID: 12739071
[TBL] [Abstract][Full Text] [Related]
10. Correlation of GLUT-1 overexpression, tumor size, and depth of invasion with 18F-2-fluoro-2-deoxy-D-glucose uptake by positron emission tomography in colorectal cancer.
Gu J; Yamamoto H; Fukunaga H; Danno K; Takemasa I; Ikeda M; Tatsumi M; Sekimoto M; Hatazawa J; Nishimura T; Monden M
Dig Dis Sci; 2006 Dec; 51(12):2198-205. PubMed ID: 17080242
[TBL] [Abstract][Full Text] [Related]
11. Autoradiographic and small-animal PET comparisons between (18)F-FMISO, (18)F-FDG, (18)F-FLT and the hypoxic selective (64)Cu-ATSM in a rodent model of cancer.
Dence CS; Ponde DE; Welch MJ; Lewis JS
Nucl Med Biol; 2008 Aug; 35(6):713-20. PubMed ID: 18678357
[TBL] [Abstract][Full Text] [Related]
12. Differential (18)F-FDG and 3'-deoxy-3'-(18)F-fluorothymidine PET responses to pharmacologic inhibition of the c-MET receptor in preclinical tumor models.
Cullinane C; Dorow DS; Jackson S; Solomon B; Bogatyreva E; Binns D; Young R; Arango ME; Christensen JG; McArthur GA; Hicks RJ
J Nucl Med; 2011 Aug; 52(8):1261-7. PubMed ID: 21764800
[TBL] [Abstract][Full Text] [Related]
13. Imaging proliferation in human leukemia-tumor bearing mice with (18)F-FLT: Comparison with (18)F-FDG PET.
Lu L; Jiang L; Guan H; Gao Y; Lu H
Hell J Nucl Med; 2012; 15(3):206-9. PubMed ID: 23106052
[TBL] [Abstract][Full Text] [Related]
14. 18F-fluoromisonidazole PET uptake is correlated with hypoxia-inducible factor-1α expression in oral squamous cell carcinoma.
Sato J; Kitagawa Y; Yamazaki Y; Hata H; Okamoto S; Shiga T; Shindoh M; Kuge Y; Tamaki N
J Nucl Med; 2013 Jul; 54(7):1060-5. PubMed ID: 23699668
[TBL] [Abstract][Full Text] [Related]
15. Simultaneous positron emission tomography (PET) assessment of metabolism with ¹⁸F-fluoro-2-deoxy-d-glucose (FDG), proliferation with ¹⁸F-fluoro-thymidine (FLT), and hypoxia with ¹⁸fluoro-misonidazole (F-miso) before and during radiotherapy in patients with non-small-cell lung cancer (NSCLC): a pilot study.
Vera P; Bohn P; Edet-Sanson A; Salles A; Hapdey S; Gardin I; Ménard JF; Modzelewski R; Thiberville L; Dubray B
Radiother Oncol; 2011 Jan; 98(1):109-16. PubMed ID: 21056487
[TBL] [Abstract][Full Text] [Related]
16. 18F-fluoromisonidazole PET/CT: a potential tool for predicting primary endocrine therapy resistance in breast cancer.
Cheng J; Lei L; Xu J; Sun Y; Zhang Y; Wang X; Pan L; Shao Z; Zhang Y; Liu G
J Nucl Med; 2013 Mar; 54(3):333-40. PubMed ID: 23401605
[TBL] [Abstract][Full Text] [Related]
17. Biological image-guided radiotherapy in rectal cancer: is there a role for FMISO or FLT, next to FDG?
Roels S; Slagmolen P; Nuyts J; Lee JA; Loeckx D; Maes F; Stroobants S; Penninckx F; Haustermans K
Acta Oncol; 2008; 47(7):1237-48. PubMed ID: 18654902
[TBL] [Abstract][Full Text] [Related]
18. 3'-Deoxy-3'-18F-fluorothymidine PET predicts response to (V600E)BRAF-targeted therapy in preclinical models of colorectal cancer.
McKinley ET; Smith RA; Zhao P; Fu A; Saleh SA; Uddin MI; Washington MK; Coffey RJ; Manning HC
J Nucl Med; 2013 Mar; 54(3):424-30. PubMed ID: 23341544
[TBL] [Abstract][Full Text] [Related]
19. Monitoring early responses to irradiation with dual-tracer micro-PET in dual-tumor bearing mice.
Wang H; Liu B; Tian JH; Xu BX; Guan ZW; Qu BL; Liu CB; Wang RM; Chen YM; Zhang JM
World J Gastroenterol; 2010 Nov; 16(43):5416-23. PubMed ID: 21086558
[TBL] [Abstract][Full Text] [Related]
20. 3'-deoxy-3'-[18F]fluorothymidine as a new marker for monitoring tumor response to antiproliferative therapy in vivo with positron emission tomography.
Barthel H; Cleij MC; Collingridge DR; Hutchinson OC; Osman S; He Q; Luthra SK; Brady F; Price PM; Aboagye EO
Cancer Res; 2003 Jul; 63(13):3791-8. PubMed ID: 12839975
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]